We are live on ! Find out more
QTTB icon

Q32 Bio

73 hedge funds and large institutions have $283M invested in Q32 Bio in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

617% more capital inflows, than outflows

Capital inflows: $125M | Capital outflows: $17.5M

211% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 9

87.22% more ownership

Funds ownership: 64.46% → 151.68% (+87%)

35% more funds holding

Funds holding: 54 → 73 (+19)

31% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 13

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $3.33M

Holders
73
Holders Change
+19
Holders Change %
+35.19%
% of All Funds
0.87%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
28
Increased
17
Reduced
13
Closed
9
Calls
–
Puts
$3.33​M
Net Calls
-⁠$3.33​M
Net Calls Change
-⁠$3.33​M

QTTB Hedge Fund Activity: Q2 2026 in Review

73 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q2 2026, worth a combined $283M — up 366% from $60.6M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new QTTB positions and 9 closed out — a net gain of 19 holders — while 17 added to existing stakes and 13 trimmed.

The largest buyer was Boxer Capital Management, opening a new position worth an estimated $26.3M. The largest seller was Carlyle Group, cutting an estimated $8.71M.

  • 73 institutional investors held Q32 Bio (QTTB) as of Q2 2026, up from 54 in Q1 2026.
  • Funds reported $283M of Q32 Bio stock for Q2 2026, up 366% quarter-over-quarter.
  • 28 funds opened new Q32 Bio positions in Q2 2026 and 9 closed out, a net change of +19 holders.
  • The largest Q32 Bio buyer in Q2 2026 was Boxer Capital Management, an estimated $26.3M added.
  • The largest Q32 Bio seller in Q2 2026 was Carlyle Group, an estimated $8.71M sold.

Based on aggregated 13F filings for Q2 2026.